Plasma and Cerebrospinal Fluid Pharmacokinetic Study of Topotecan in Nonhuman Primates

Cancer Research

Volumn 53, Issue 4, 1993, Pages 725-727

  Cole, Diane E ^b   Balis, Frank M ^b   Godwin, Karen ^b   Poplack, David G ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; GYRASE INHIBITOR; TOPOTECAN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG STABILITY; DRUG STRUCTURE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RHESUS MONKEY;

ANIMAL; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; HYDROLYSIS; MACACA MULATTA; MALE; TOPOTECAN;

EID: 0027511840     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Maxwell, A. and Gellert, M. Mechanistic aspects of DNA topoisomerases. Adv. Protein Chem. 38: 69-107, 1986.
2. Johnson, R. K. McCabe, F. L. Faucette, L. F. Hertzberg, R. P. Kingsbury, W. D. Boehm, J. C. Caranfa, M. J. Holden, K. G. SK&F 104864. a water soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models. Proc. Am. Assoc. Cancer Res. 30: 623, 1989.
3. Liu, L. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58: 351-375, 1989.
4. Houghton, P. J. Cheshire, P. J. Myers, L. and Houghton, J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxy camptothecin (topotecan) against xenografts derived from adult and childhood tumors. Ann. Oncol. 3 (Suppl. 1): 84, 1992.
5. Haas, N. B. Hudes, G. R. Walczak, J. LaCreta, P. Brennan, J. Ozols, R. R. and O'Dwyer, P. J. Phase I trial of topotecan on a weekly 24-hour infusional schedule. Ann. Oncol. 3 (Suppl. 1): 84, 1992.
6. Burns, H. Kuhn, J. Wall, J. Eckardt, J. Rodriguez, G. Johnson, R. Weiss, G. Shaffer, D. and vonHoff, D. Early clinical trials of topotecan, a new topoisomerase I inhibitor. Ann. Oncol. 3 (Suppl. 1): 118, 1992.
7. Sirott, M. N. Saltz, L. Young, C. Tong, W, Trochanowski, B. Niedzwiecki, D. Toomasi, F. and Kelsen, D. Phase I and clinical pharmacologic study of intravenous topotecan. Proc. Am. Soc. Clin. Oncol. 10: 104, 1991.
8. Rowinsky, E. K. Grochow, L. B. Hendricks, C. B. Ettinger, D. S. Forastiere, A. A. Hurowitz, L. A. McGuire, W. P. Sartorius, S. S. Lubejko, B. G. Kaufmann, S. H. and Donehower, R. C. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol. 10: 647-656, 1992.
9. Cole, D. Blaney, S. Balis, F. Reaman, G. Craig, C. Feusner, J. Dinndorf, P. Krailo, M. Ames, M. Hammond, D. and Poplack, D. A. phase I and pharmacokinetic study of topotecan in pediatric patients. Proc. Am. Soc. Clin. Oncol. 11: 116, 1992.
10. Verweij, J. Lund, B. Planting. A. S. T. deBoer, M. Koier, I. and Hansen, H. H. Clinical studies with topotecan: the EORTC experience. Ann. Oncol. 3 (Suppl. 1): 118, 1992.
11. Kuhn, J. Burns, S. Wall, J. Brown. T. Cagnola. J. Havlin, K. Weiss. G. Koeller, J. Rodriguez, G. Smith, B. Johnson, B. Johnson, R. and Von Hoff, D. Pharmacokinetics of the topoisomerase I inhibitor, SK&F 104864. Proc. Am. Soc. Clin. Oncol. 9: 70, 1990.
12. Reid, J. M. Burch, P. A. Benson, L. M. Gilbert, J. A. Richardson, R. L. and Ames, M. M. Phase 1 and clinical and pharmacologic evaluation of topotecan administered by a 24 hour continuous infusion. Proc. Am. Assoc. Cancer Res. 33: 259, 1992.
13. Gottlieb, J. A. Guarino, A. M. Call, J. B. Oliverio, V. T. and Block, J. B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep. 54: 461-470, 1970.
14. Guide for the Care and Use of Laboratory Animals Department of Health, Education and Welfare Publication (NIH) 85-123, revised Washington, DC; U.S. Government Printing Office, 1988.
15. McCully, C. L. Balis, F M. Bacher, J. Phillips, J. and Poplack, D. G. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab. Anim. Sci. 40: 520-525, 1990.
16. Knott, G. D. MLAB: a mathematical modeling tool. Comput. Programs Biomed. 10: 271-280. 1979.
17. Yamaoka, K. Nakagawa, T. and Uno, T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6: 165-175, 1978.
18. Gibaldi, M. and Perrier, D. Estimation of areas. In: Swarbrick, J. (ed.). Pharmacokinetics, Ed. 2, pp. 445-449. New York: Marcel Dekker, Inc. 1982.
19. Perrier, D. and Mayersohn, M. Noncompartmental determination of steady state volume of distribution for any mode of administration. J. Pharm. Sci. 71: 372-373, 1982.
20. Poplack, D. G. Bleyer, W. A. Wood, J. H. Kostolich. M. Savitch, J. L. and Ommaya, A. K. A primate model for study of methotrexate pharmacokinetics in the central nervous system. Cancer Res. 37: 1982-1985, 1977.
21. Hande, K. R. Wedlund, P. J. Noone, R. M. Wildinson, G. R. Greco, F. A. and Wolff, S. N. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res. 44: 379-382, 1984.
22. Benjamin, R. S. Wiemik, P. H. and Bachur. N. R. Adriamycin chemotherapy- efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer (Phila.), 33: 19-27, 1974.